Can 5-FU be substituted for adjuvant capecitabine for a dialysis dependent patient with triple negative breast cancer s/p neoadjuvant chemotherapy followed by mastectomy showing small residual disease?

I would not substitute 5-FU in this situation.

Although the CREATE-X trial showed a survival benefit for adjuvant capecitabine in women who do not achieve pCR with neoadjuvant chemotherapy in a subset analysis of women with triple negative breast cancer, there are reasons to be concerned about these ...